Companies: 10,795·Total market cap: $144.5T
Humacyte, Inc.

Humacyte, Inc.

HUMANASDAQHealthcare● Active
$1.38
+$0.03(+2.22%)
Market Cap$231840000
P/E Ratio
52W High$2.93
52W Low$0.547
Overview

Humacyte, Inc. (HUMA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001818382 · HUMA · NASDAQ · as of Jun 8, 2026

Filing snapshot

471
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001818382 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-27
Fiscal Year End
Mar 27, 2026
Accession No.
0001818382-26-000004
Primary Document
huma-20251231.htm
Source: data.sec.gov · CIK 0001818382 · Accession 0001818382-26-000004

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-13
8-KCurrent Report
FORM 8-K
2026-06-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-06-05
View
S-8Employee Stock Plan Registration
FORM S-8
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-13
View
8-KCurrent Report
FORM 8-K
2026-05-08
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-27
View
8-KCurrent Report
FORM 8-K
2026-04-24
View
PRE 14APRE 14A
PRE 14A
2026-04-17
View
10-KAnnual Report
10-K
2026-03-27
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-24
View
8-KCurrent Report
FORM 8-K
2026-03-19
View
424B3424B3
424B3
2026-03-19
View
8-KCurrent Report
FORM 8-K
2026-03-19
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-09
View
8-KCurrent Report
FORM 8-K
2025-12-16
View
Showing 1–15 of 259 filingsForm 4 / 144 hidden· 471 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001818382  |  Exchange: NASDAQ · Healthcare

Humacyte, Inc. (NASDAQ: HUMA) has submitted 471 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001818382, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Humacyte, Inc.'s most comprehensive regulatory disclosure. The most recent Humacyte, Inc. 10-K was filed on 2026-03-27 for fiscal year ending 2026. Historical HUMA 10-K annual reports are available from 2020 through 2026.

Investors researching Humacyte, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

HUMA SEC Filings · 8 questions

Humacyte, Inc. (HUMA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 471 filings and access original documents at no cost. Humacyte, Inc.'s CIK is 0001818382.

HUMA SEC filingsHumacyte, Inc. SEC documentsfind HUMA 10-K